NASDAQ:XXII 22nd Century Group Q3 2023 Earnings Report $1.68 +0.05 (+3.07%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.68 0.00 (-0.30%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast 22nd Century Group EPS ResultsActual EPS-$620,006.40Consensus EPS -$723,340.80Beat/MissBeat by +$103,334.40One Year Ago EPSN/A22nd Century Group Revenue ResultsActual Revenue$17.81 millionExpected Revenue$20.06 millionBeat/MissMissed by -$2.25 millionYoY Revenue GrowthN/A22nd Century Group Announcement DetailsQuarterQ3 2023Date11/6/2023TimeN/AConference Call DateMonday, November 6, 2023Conference Call Time7:00AM ETUpcoming Earnings22nd Century Group's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) 22nd Century Group Earnings Headlines22nd Century Submits Comments to FDA in Support of Proposed Reduced Nicotine Content MandateSeptember 30, 2025 | globenewswire.com22nd Century Group Stock Rockets 30% Premarket On Scoring $9.5M Insurance Payday, Retail Traders Pile InSeptember 25, 2025 | msn.comGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" Eifrig says history shows it could be on the verge of its biggest bull run in over half a century.October 6 at 2:00 AM | Stansberry Research (Ad)22nd Century Stock Jumps 39% Pre-Market On $9.5 Million Insurance SettlementSeptember 25, 2025 | benzinga.com22nd Century Group, Inc. Secures $9.5 Million Insurance Settlement, Positioned for Growth and Profitability by 2026September 24, 2025 | quiverquant.comQ22nd Century Secures $9.5 Million Cash Proceeds from Settlement of Insurance ClaimSeptember 24, 2025 | globenewswire.comSee More 22nd Century Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 22nd Century Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 22nd Century Group and other key companies, straight to your email. Email Address About 22nd Century Group22nd Century Group (NASDAQ:XXII)., founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers. Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients. GenCanna produces and distributes hemp-derived phytocannabinoids—including cannabidiol (CBD)—in bulk and finished-goods formats for nutraceutical, wellness and personal care manufacturers across North America and select international markets. The company’s integrated value chain encompasses seed development, greenhouse propagation, analytical testing and large-scale processing. In addition to product commercialization, 22nd Century offers contract research and development services that leverage its greenhouse, field and laboratory facilities. Its R&D capabilities support trait discovery, regulatory compliance testing and pilot-scale production, enabling partnerships with government agencies, clinical researchers and industry stakeholders. With research centers in New York and North Carolina, the company pursues ongoing collaborations aimed at advancing low-nicotine tobacco science and expanding plant-based cannabinoid applications globally.View 22nd Century Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
